Coronary Atheroma Progression under Glucose Control with ConTInuous Glucose Monitoring

Conditions

Coronary artery disease in patients with type 2 diabetes mellitus Coronary artery disease, atherosclerosis, type 2 diabetes mellitus, intravascular imaging

Salib A, Kataoka Y, Nicholls SJ, Kitahara S, Funabashi S, Makino H, Matsubara M, Matsuo M, Omura-Ohata Y, Koezuka R, Tochiya M, Tamanaha T, Tomita T, Honda-Kohmo K, Noguchi M, Mitsui K, Murai K, Iwai T, Sawada K, Matama H, Honda S, Fujino M, Yoneda S, Nakao K, Takagi K, Otsuka F, Asaumi Y, Hosoda K, Yasuda S, Noguchi T.

2025-12-15

10.1016/j.jacl.2025.12.011

Angioprotein-like 3 and atheroma progression in statin-treated type 2 diabetic patients with coronary artery disease: the pre-specified analysis from the OPTIMAL randomized controlled trial

Satoshi Kitahara, Yu Kataoka, Sayaka Funabashi, Hisashi Makino, Kōichi Nakao et al. (13 authors)

European Heart Journal2024-10-01

10.1093/eurheartj/ehae666.2786

Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trial.

Kataoka Y, Kitahara S, Funabashi S, Makino H, Matsubara M, Matsuo M, Omura-Ohata Y, Koezuka R, Tochiya M, Tamanaha T, Tomita T, Honda-Kohmo K, Noguchi M, Murai K, Sawada K, Iwai T, Matama H, Honda S, Fujino M, Nakao K, Yoneda S, Takagi K, Otsuka F, Asaumi Y, Hosoda K, Nicholls SJ, Yasuda S, Noguchi T.

2024-04-044 citations

10.1016/j.athplu.2024.03.001

Lowering apolipoprotein C-III associates with regression of lipidic plaque materials in type 2 DM patients with coronary artery disease: the pre-specified analysis from the OPTIMAL trial

Satoshi Kitahara, Yuko Kataoka, Sayaka Funabashi, Kota Murai, Takamasa Iwai et al. (15 authors)

European Heart Journal2023-11-01

10.1093/eurheartj/ehad655.2508

The effect of continuous glucose monitoring-guided glycemic control on progression of coronary atherosclerosis in type 2 diabetic patients with coronary artery disease: The OPTIMAL randomized clinical trial.

Kataoka Y, Kitahara S, Funabashi S, Makino H, Matsubara M, Matsuo M, Omura-Ohata Y, Koezuka R, Tochiya M, Tamanaha T, Tomita T, Honda-Kohmo K, Noguchi M, Maruki M, Kanai E, Murai K, Iwai T, Sawada K, Matama H, Honda S, Fujino M, Yoneda S, Takagi K, Otsuka F, Asaumi Y, Hosoda K, Nicholls SJ, Yasuda S, Noguchi T.

2023-08-235 citations

10.1016/j.jdiacomp.2023.108592

The efficacy of glycemic control with continuous glucose monitoring on atheroma progression: rationale and design of the Observation of Coronary Atheroma Progression under Continuous Glucose Monitoring Guidance in Patients with Type 2 Diabetes Mellitus (OPTIMAL).

Kataoka Y, Hosoda K, Makino H, Matsubara M, Matsuo M, Ohata Y, Koezuka R, Tamanaha T, Tomita T, Honda-Kohmo K, Noguchi M, Son C, Nishimura K, Asaumi Y, Miyamoto Y, Noguchi T, Yasuda S.

2019-10-015 citations

10.21037/cdt.2019.09.02

Interventions

A. glycemic management under CGM use B. glycemic management under HbA1c measurement

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male of female between 20 and 80 years of age 2. Type 2 diabetic patients with coronary artery disease 3. Subjects requiring PCI 4. The presence of mild stenosis in the non-target vessel (percent diameter stenosis between 10-50%) identified by coronary angiography within 12 weeks prior to PCI 5. HbA1c betweeen 7.0% and 10.0% 6. HbA1c less than 10.0% in subjects who receive insulin, sulfonylurea or nateglinide 7. Ability to understand the requirements of the study and to provide informed consent

Exclusion criteria

Exclusion criteria: 1. very tortuous coronary artery and/or severe calcification which is unsuitable for intravascular imaging 2. Subjects with severe renal dysfunction (estimated glomerular filtration rate < 40 mL/min/1.73m2) 3. the absence of any atherosclerotic lesions in the non-target vessel 4. those who take PCSK9 inhibitor 5. Pregnancy 6. Current enrolment in another investing device or drug study 7. unsuitable subject according to the investigator's discretion

Design outcomes

Primary

Measure	Time frame
Absolute change in plaque volume	—

Secondary

Measure	Time frame
Absolute change in percent atheroma volume Absolute change in lipid core burden index the frequency of hypoglycemia	—

Contacts

Public ContactYu Kataoka

National Cerebral & Cardiovascular Center

yu.kataoka@ncvc.go.jp+81-6-6833-5012

Outcome results

None listed